Compare Becton Dickinson and Co (BDX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs GeneDx Holdings Corp — how do they compare? Becton Dickinson and Co trades at $180.5 (market cap $49.41B), while GeneDx Holdings Corp trades at $81.89 (market cap $2.44B). The key difference: Becton Dickinson and Co is far larger — about 20.3× GeneDx Holdings Corp's market cap, and Becton Dickinson and Co pays a 2.32% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| BDX | WGS | |
|---|---|---|
Market Cap | $49.41B | $2.44B |
Sector | Health | Technology |
52-Week High | $185.39 | $167.51 |
52-Week Low | $138.62 | $34.51 |
Enterprise Value | $65.51B | $2.48B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
